Skip Navigation


European Heart Journal Advance Access originally published online on May 24, 2007
European Heart Journal 2007 28(13):1541-1542; doi:10.1093/eurheartj/ehm169
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/13/1541    most recent
ehm169v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Stellbrink, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stellbrink, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

It's the metabolism, stupid! Why electrophysiologists should be interested in biomarkers of heart failure

Christoph Stellbrink

Department of Cardiology and Intensive Care Medicine, Bielefeld Medical Centre1, Staedtische Kliniken Bielefeld, Teutoburger Strasse 50, 33604 Bielefeld, Germany

Corresponding author. Tel: +49 521 5813401; fax: +49 521 5813498. E-mail address: christoph.stellbrink@sk-bielefeld.de

This editorial refers to ‘Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony’ by F.M. Fruhwald et al., on page 1592

The first 10% of the full text of this article appears below.

Cardiac resynchronization therapy (CRT) has emerged as a new standard in the treatment of patients with moderate-to-advanced heart failure and ventricular dyssynchrony. The recently actualized ESC/AHA/ACC heart failure guidelines have classified CRT as a class I indication in patients with reduced ejection fraction and ventricular dyssynchrony (QRS width ≥ 120 ms) who remain symptomatic (NYHA III–IV) despite optimal medical therapy to improve symptoms, hospitalizations, and mortality.1 These criteria have been derived mainly from data of the COMPANION2 and CARE-HF3 trials. So far, so good. Why should we be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony
Friedrich M. Fruhwald, Astrid Fahrleitner-Pammer, Rudolf Berger, Francisco Leyva, Nick Freemantle, Erland Erdmann, Daniel Gras, Lukas Kappenberger, Luigi Tavazzi, Jean-Claude Daubert, and John G.F. Cleland
EHJ 2007 28: 1592-1597. [Abstract] [Full Text]